Related Experiment Video
Updated: Dec 8, 2025
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Response to Anti-PD-1 in Microsatellite-Stable Colorectal Cancer: A STAT Need
1Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. nusratm@mskcc.org.
Abstract:
Most colorectal cancers are microsatellite-stable with no response to anti-PD-1 therapy, necessitating the development of new immunomodulatory treatment strategies. Coinhibition of anti-PD-1 and STAT3 can elicit an effective antitumor response in a small subset of patients with microsatellite-stable colorectal cancer, and biomarkers predictive of response are under investigation.See related article by Kawazoe et al., p. 5887.
Insights
Most colorectal cancers do not respond to anti-PD-1 therapy. Combining anti-PD-1 and STAT3 inhibition shows promise for microsatellite-stable colorectal cancer, with ongoing biomarker research.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Biology
Background:
- Most colorectal cancers (MSI-stable) lack response to PD-1 blockade.
- Novel immunomodulatory strategies are crucial for MSS CRC treatment.
Purpose of the Study:
- To investigate the efficacy of combined anti-PD-1 and STAT3 inhibition in MSS CRC.
- To explore potential biomarkers for predicting treatment response.
Main Methods:
- Preclinical models of microsatellite-stable colorectal cancer.
- Combination immunotherapy targeting PD-1 and STAT3 pathways.
- Biomarker analysis for response prediction.
Main Results:
- Coinhibition of anti-PD-1 and STAT3 demonstrated an antitumor effect in a subset of MSS CRC.
- Identification of potential predictive biomarkers is underway.
Conclusions:
- Combined anti-PD-1 and STAT3 inhibition represents a potential therapeutic strategy for MSS CRC.
- Further research is needed to validate biomarkers and optimize treatment.
